Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1

Molecular Nutrition and Food Research

Volumn 55, Issue 11, 2011, Pages 1677-1689

  Abusnina, Abdurazzag ^a   Keravis, Thérèse ^a   Yougbaré, Issaka ^a   Bronner, Christian ^a   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

CAMP cGMP; Cancer; DNMT1; Nimodipine; Rolipram

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; ISOENZYME; MESSENGER RNA; NUCLEAR PROTEIN; PDE1A PROTEIN, MOUSE; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT PROTEIN; TUMOR PROTEIN; UHRF1 PROTEIN, MOUSE;

ANIMAL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; ISOENZYMES; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHODIESTERASE INHIBITORS; RECOMBINANT PROTEINS; RNA, MESSENGER;

MURINAE;

EID: 80155147161     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100307     Document Type: Article

References (64)

1. Menon, L. G., Kuttan, R., Kuttan, G., Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 1995, 95, 221-225.
2. Aggarwal, B. B., Kumar, A., Bharti, A. C., Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23, 363-398.
3. Duvoix, A., Blasius, R., Delhalle, S., Schnekenburger, M. et al., Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005, 223, 181-190.
4. Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B., Diederich, M., Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 2008, 76, 1340-1351.
5. Sherr, C. J., Roberts, J. M., CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512.
6. Aggarwal, B. B., Banerjee, S., Bharadwaj, U., Sung, B. et al., Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem. Pharmacol. 2007, 73, 1024-1032.
7. Liu, E., Wu, J., Cao, W., Zhang, J. et al., Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neurooncol. 2007, 85, 263-270.
8. Srivastava, R. K., Chen, Q., Siddiqui, I., Sarva, K., Shankar, S., Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 2007, 6, 2953-2961.
9. Sahu, R. P., Batra, S., Srivastava, S. K., Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br. J. Cancer 2009, 100, 1425-1433.
10. Arima, Y., Hirota, T., Bronner, C., Mousli, M. et al., Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 2004, 9, 131-142.
11. Achour, M., Jacq, X., Rondé, P., Alhosin, M. et al., The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 2008, 27, 2187-2197.
12. Hopfner, R., Mousli, M., Jeltsch, J. M., Voulgaris, A. et al., ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase II alpha expression. Cancer Res. 2000, 60, 121-128.
13. Arita, K., Ariyoshi, M., Tochio, H., Nakamura, Y., Shirakawa, M., Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 2008, 455, 818-821.
14. Avvakumov, G. V., Walker, J. R., Xue, S., Li, Y. et al., Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 2008, 455, 822-825.
15. Hashimoto, H., Horton, J. R., Zhang, X., Bostick, M. et al., The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 2008, 455, 826-829.
16. Unoki, M., Nishidate, T., Nakamura, Y., ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004, 23, 7601-7610.
17. Mousli, M., Hopfner, R., Abbady, A. Q., Monté, D. et al., ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br. J. Cancer 2003, 89, 120-127.
18. Pita, J. M., Banito, A., Cavaco, B. M., Leite, V., Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br. J. Cancer 2009, 101, 1782-1791.
19. Conti, M., Beavo, J., Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76, 481-511.
20. Bender, A. T., Beavo, J. A., Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
21. Lugnier, C., Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109, 366-398.
22. Favot, L., Keravis, T., Holl, V., Le Bec, A., Lugnier, C., VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb. Haemost. 2003, 90, 334-343.
23. Favot, L., Keravis, T., Lugnier, C., Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb. Haemost. 2004, 92, 634-645.
24. Savai, R., Pullamsetti, S. S., Banat, G. A., Weissmann, N. et al., Targeting cancer with phosphodiesterase inhibitors. Expert Opin. Invest. Drugs 2010, 19, 117-131.
25. Alhosin, M., Abusnina, A., Achour, M., Sharif, T. et al., Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem. Pharmacol. 2010, 79, 1251-1260.
26. Abusnina, A., Alhosin, M., Keravis, T., Muller, C. D. et al., Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell. Signalling 2011, 23, 152-160.
27. Keravis, T., Thaseldar-Roumié, R., Lugnier, C., Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol. Biol. 2005, 307, 63-74.
28. Lugnier, C., Schoeffter, P., Le Bec, A., Strouthou, E., Stoclet, J. C., Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 1986, 35, 1743-1751.
29. Kameni-Tcheudji, J. F., Lebeau, L., Virmaux, N., Maftei, C. G. et al., Molecular organization of bovine rod cGMP-phosphodiesterase 6. J. Mol. Biol. 2001, 310, 781-791.
30. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J., Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
31. (2+) responses in endothelial cells. Br. J. Pharmacol. 2008, 154, 82-92.
32. Livak, K. J., Schmittgen, T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408.
33. Marivet, M. C., Bourguignon, J. J., Lugnier, C., Mann, A. et al., Inhibition of cyclic adenosine-3′, 5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 1989, 32, 1450-1457.
34. Lugnier, C., Bruch, M., Stoclet, J. C., Strub, M. P. et al., Substituted carbostyrils as inhibitors of cyclic AMP phosphodiesterase. Eur. J. Med. Chem. 1985, 20, 121-125.
35. Coste, H., Grondin, P., Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem. Pharmacol. 1995, 50, 1577-1585.
36. Lugnier, C., Follénius, A., Gérard, D., Stoclet, J. C., Bepridil and flunarizine as calmodulin inhibitors. Eur. J. Pharmacol. 1984, 98, 157-158.
37. Narita, M., Murata, T., Shimizu, K., Nakagawa, T. et al., A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Oncol. Rep. 2007, 17, 1133-1139.
38. Li, W., Sanki, A., Karim, R. Z., Thompson, J. F. et al., The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006, 38, 287-301.
39. Ling, Y. H., el-Naggar, A. K., Priebe, W., Perez-Soler, R., Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol. 1996, 49, 832-841.
40. Bronner, C., Achour, M., Arima, Y., Chataigneau, T. et al., The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol. Ther. 2007, 115, 419-434.
41. Daskalos, A., Oleksiewicz, U., Filia, A., Nikolaidis, G. et al., UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer. 2011, 117, 1027-1037.
42. Abbady, A. Q., Bronner, C., Bathami, K., Muller, C. D. et al., TCR pathway involves ICBP90 gene down-regulation via E2F binding sites. Biochem. Pharmacol. 2005, 70, 570-579.
43. Thompson, W. J., Piazza, G. A., Li, H., Liu, L. et al., Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000, 60, 3338-3342.
44. Zhu, B., Strada, S., Stevens, T., Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289, L196-L206.
45. Moon, E.Y., Lerner, A., Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res. 2002, 62, 5711-5719.
46. Yoon, J. T., Palazzo, A.F., Xiao, D., Delohery, T. M. et al., CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. Mol. Cancer Ther. 2002, 1, 393-404.
47. Zhu, B., Vemavarapu, L., Thompson, W. J., Strada, S. J., Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J. Cell. Biochem. 2005, 94, 336-350.
48. Fukumoto, S., Koyama, H., Hosoi, M., Yamakawa, K. et al., Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ. Res. 1999, 85, 985-991.
49. Sato, J., Nair, K., Hiddinga, J., Eberhardt, N. L. et al., eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc. Res. 2000, 47, 697-706.
50. Bender, A. T., in: Beavo J. A., Francis, S. H., Houslay, M. D. (Eds.), Cyclic Nucleotide Phosphodiesterases in Health and Disease, CRC Press, Boca Raton 2006, pp. 35-54.
51. Vasta, V., Sonnenburg, W. K., Yan, C., Soderling, S.H. et al., Identification of a new variant of PDE1A calmodulin-stimulated cyclic nucleotide phosphodiesterase expressed in mouse sperm. Biol. Reprod. 2005, 73, 598-609.
52. Yu, T., Li, J., Sun, H., C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother. Pharmacol. 2010, 66, 999-1003.
53. Chatterjee, S. J., Pandey, S., Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol. Ther. 2011, 11, 216-228.
54. Chen, L. X., He, Y. J., Zhao, S. Z., Wu, J. G. et al., Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol. Ther. 2011, 11, 229-235.
55. Tung, Y. T., Chen, H. L., Lai, C. W., Shen, C. J. et al., Curcumin reduces pulmonary tumorigenesis in vascular endothelial growth factor (VEGF)-overexpressing transgenic mice. Mol. Nutr. Food Res. 2011, 55, 1036-1043.
56. Shimizu, K., Murata, T., Watanabe, Y., Sato, C. et al., Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Res. 2009, 29, 1119-1122.
57. Gonçalvez, R. L., Lugnier, C., Keravis, T., Lopes, M. J. et al., The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur. J. Pharmacol. 2009, 620, 78-83.
58. Wu, S. N., Li, H. F., Chiang, H. T., Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem. Pharmacol. 2001, 61, 877-892.
59. Webster, W. S., Leibovich, B. C., Exisulind in the treatment of prostate cancer. Expert Rev. Anticancer Ther. 2005, 5, 957-962.
60. Zhu, B., Strada, S. J., The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr. Top. Med. Chem. 2007, 7, 437-454.
61. Govindan, R., Wang, X., Baggstrom, M. Q., Burdette-Radoux, S. et al., A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J. Thorac. Oncol. 2009, 4, 220-226.
62. Whitehead, C. M., Earle, K. A., Fetter, J., Xu, S. et al., Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol. Cancer Ther. 2003, 2, 479-488.
63. Giladi, N., Kazanov, D., Shpitz, B., Aroch, I. et al., Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin. Investig. Drugs. 2010, 19, S117-S124.
64. Arozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C. et al., Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 2011, 19, 45-57.